Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.
About 50 patients with a proven breast cancer and bone metastases will be included. First step : staging * nuclear bone scan * Positron Emission Tomography (PET/CT) * MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration Aim : * Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results. * To calculate cut-off values for DWI for bone and visceral metastases. Second step : therapy follow-up/therapy assessment. * Two groups of patients (oncologist takes the decision about therapy) 1. Patients treated by chemotherapy 2. Patients treated by hormonal therapy * on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed. End-point: Whole body MR with DWI is useful and reliable to assess the treatment response.
Study Type
OBSERVATIONAL
Enrollment
50
University Hospitals Leuven
Leuven, Belgium
RECRUITINGValidation of whole body diffusion weighted MRI in breastcancer patients
whole body MRI will be correlated to the nucleair bone scan and PET-CT
Time frame: 6 months
Whole body MRI with diffusion weighted imaging is a reliable imaging tool for therapy assessment
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.